Phathom Pharmaceuticals, Inc. Investigated by the Portnoy Law Firm
LOS ANGELES, Aug. 10, 2026 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises Phathom Pharmaceuticals, Inc., (“Phathom" or the "Company") (NASDAQ: PHAT) investors that the firm has initiated an investigation into possible securities fraud, and may file a class action on behalf of investors.
Investors are encouraged to contact attorney Lesley F. Portnoy, by phone 844-767-8529 or email: lesley@portnoylaw.com, to discuss their legal rights, or join the case via https://portnoylaw.com/phathom-pharmaceuticals-inc. The Portnoy Law Firm can provide a complimentary case evaluation and discuss investors’ options for pursuing claims to recover their losses.
Phathom operates as a commercial-stage enterprise with its top-line revenue tightly tied to a single market-ready therapy, VOQUEZNA (vonoprazan). Given that the firm's overall financial health relies heavily on the commercial scaling of this flagship asset, its top-line guidance serves as the core determinant of its market valuation. The guidance revision shaved $10 million off the low end and $20 million off the high end of its previous forecast window of $320 million to $345 million. Leading into 2026, the business had actively scaled its sales force, assuring shareholders that it entered the second quarter with "more than 290 reps in place to start Q2," while outlining a trajectory toward achieving "$1 billion in annual revenue from gastroenterology prescriptions." Just weeks following those statements, management lowered its full-year 2026 revenue expectations.
The Portnoy Law Firm represents investors in pursuing claims caused by corporate wrongdoing. The Firm’s founding partner has recovered over $5.5 billion for aggrieved investors. Attorney advertising. Prior results do not guarantee similar outcomes.
Lesley F. Portnoy, Esq.
Admitted CA, NY and TX Bar
lesley@portnoylaw.com
310-692-8883
www.portnoylaw.com
Attorney Advertising
© Copyright Globe Newswire, Inc. All rights reserved. The information contained in this news report may not be published, broadcast or otherwise distributed without the prior written authority of Globe Newswire, Inc.
